Ghilardi, Carmen; Moreira-Barbosa, Catarina; Brunelli, Laura; Ostano, Paola; Panini, Nicolo; Lupi, Monica; Anastasia, Alessia; Fiordaliso, Fabio; Salio, Monica; Formenti, Laura; Russo, Massimo; Arrigoni, Edoardo; Chiaradonna, Ferdinando; Chiorino, Giovanna; Draetta, Giulio; Marszalek, Joseph R.; Vellano, Christopher P.; Pastorelli, Roberta; Bani, MariaRosa; Decio, Alessandra; Giavazzi, Raffaella published the artcile< PGC1α/β expression predicts therapeutic response to oxidative phosphorylation inhibition in ovarian cancer>, Quality Control of 112-63-0, the main research area is PGC1alpha beta anticancer oxidative phosphorylation inhibitor ovarian cancer.
Ovarian cancer is the deadliest gynecol. cancer, and novel therapeutic options are crucial to improve overall survival. Here we provide evidence that impairment of oxidative phosphorylation (OXPHOS) can help control ovarian cancer progression, and this benefit correlates with expression of the two mitochondrial master regulators PGC1α and PGC1β. In orthotopic patient-derived ovarian cancer xenografts (OC-PDX), concomitant high expression of PGC1α and PGC1β (PGC1α/β) fostered a unique transcriptional signature, leading to increased mitochondrial abundance, enhanced tricarboxylic acid cycling, and elevated cellular respiration that ultimately conferred vulnerability to OXPHOS inhibition. Treatment with the respiratory chain complex I inhibitor IACS-010759 caused mitochondrial swelling and ATP depletion that consequently delayed malignant progression and prolonged the lifespan of high PGC1α/β-expressing OC-PDX-bearing mice. Conversely, low PGC1α/β OC-PDXs were not affected by IACS-010759, thus pinpointing a selective antitumor effect of OXPHOS inhibition. The clin. relevance of these findings was substantiated by anal. of ovarian cancer patient datasets, which showed that 25% of all cases displayed high PGC1α/β expression along with an activated mitochondrial gene program. This study endorses the use of OXPHOS inhibitors to manage ovarian cancer and identifies the high expression of both PGC1α and β as biomarkers to refine the selection of patients likely to benefit most from this therapy.
Cancer Research published new progress about Acute myeloid leukemia. 112-63-0 belongs to class esters-buliding-blocks, and the molecular formula is C19H34O2, Quality Control of 112-63-0.
Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics